#$meso

2019-nCoV virus pathogenicity was tested in cell culture, with damage to the cells on the right upper corner being visible. Such assays may help devise treatments for COVID-19. Credit: Pasteur Institut Pasteur/CNR for Respiratory Viruses at the Institut Pasteur.

Could two stem cell biotechs Athersys and Mesoblast help in the battle against the novel coronavirus?

Stem cells, ARDS, and COVID-19

I’v…

Stem cell news bites: Mesoblast, BioTime, MS, FDA Warning, & More

Stem cell studies continue to make big news with a mixed bag of trends, and some good stem cell news and others not so much.

Mesoblast ($MESO) had its stock suspended for quite so time recently in anticipation of a big announcement. When that news came todayit was discouraging in the form of its partner Teva choosing to end their relationship with Mesoblast on a stem cell heart disease trial.…

Mesoblast stock on hold: Poll if you expect good or bad news

Adult stem cell biotech Mesoblast ($MESO) is in the unusual situation currently of having its stock on hold. This is a relatively rare event and usually portends some kind of major news. The hold is expected to run from June 1 to June 10.

Mesoblast will announce ““material corporate developments with respect to certain assets of the company”.

This could involve good or bad news related to one of…